{"url_path":"/sec/anvs/8-k/2026-05-20/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-064514-index.html","accession_number":"0001104659-26-064514","cik":"0001477845","ticker":"ANVS","issuer_name":"Annovis Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-064514-index.html","primary_entity_key":"0001477845","primary_entity_name":"Annovis Bio, Inc."},"word_count":447,"has_tables":true,"body_markdown":"**Item 1.01**\n**Entry into a Material Definitive Agreement.**\n\n \n\nOn May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”),\ndated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed\nto issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”),\n$0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase up\nto an aggregate of 7,105,500 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise\nof the Warrants, the “Warrant Shares”). The Warrants are immediately exercisable, expire six years from the date of issuance\nand have an exercise price equal to $2.25 per share of Common Stock. The combined offering price of each Share and accompanying nine-tenths\nof a Warrant is $1.90 per share. The gross proceeds to the Company from the Offering are expected to be approximately $15 million, before\ndeducting offering expenses payable by the Company.\n\n \n\nThe Offering is expected to close on or about\nMay 21, 2026, subject to the satisfaction of customary closing conditions. The Company currently plans to use the net proceeds from the\nOffering, for the continued clinical development of the Company’s lead compound Buntanetap in clinical studies for for Alzheimer’s\ndisease and Parkinson’s disease, and for working capital and general corporate purposes.\n\n \n\nThe Underwriting Agreement contains customary\nrepresentations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company,\nincluding for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of\nthe parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made\nonly for the purposes of such agreement and as of the specific dates, were solely for the benefit of the parties to such agreement and\nmay be subject to limitations agreed upon by the contracting parties.\n\n \n\nThe Offering was made pursuant to the Company’s\neffective shelf registration statement on Form S-3 (File No. 333-276814), which was declared effective on February 12,\n2024, and a related base prospectus and prospectus supplement thereunder dated May 19, 2026.\n\n \n\nThe legal opinion of Loeb & Loeb LLP relating\nto the Shares, Warrants and Warrant Shares is filed herewith as Exhibit 5.1.\n\n \n\n2\n\n \n\n \n\nThe foregoing description of the terms and conditions\nof the Undewriting Agreement and the Warrant do not purport to be complete and are qualified in its entirety by the full text of\neach of such document, copies of which are attached hereto as Exhibits 10.1 and 4.1, respectively, and incorporate by reference\nherein."}